Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MorphoSys AG - American Depositary Shares (NQ:MOR)

18.96 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MorphoSys AG - American Depositary Shares

< Previous 1 2 3 4 Next >
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
Via ACCESSWIRE
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
From MorphoSys AG
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DM, SHCR, MOR, ALE on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Invitation to MorphoSys' Full Year Results 2023 Conference Call on March 14, 2024
Via ACCESSWIRE
MorphoSys AG (NASDAQ: MOR) Near the Top of Equities by Percentage Gain on 2/5
Via Investor Brand Network
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, MOR, BEST, MGOL on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
From MorphoSys AG
Via Business Wire
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
Via ACCESSWIRE
MorphoSys AG (NASDAQ: MOR) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
Invitation to MorphoSys' Third Quarter and First Nine Months 2023 Financial Results Conference Call on November 16, 2023
Via ACCESSWIRE
MorphoSys AG Reports First Quarter 2024 Financial Results
From MorphoSys AG
Via Business Wire
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
Via ACCESSWIRE
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
From MorphoSys AG
Via Business Wire
MorphoSys' Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
Via ACCESSWIRE
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
Via ACCESSWIRE
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From MorphoSys AG
Via Business Wire
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
Via ACCESSWIRE
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
Via ACCESSWIRE
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Via ACCESSWIRE
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
From MorphoSys AG
Via Business Wire
Ad hoc: MorphoSys' Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
Via ACCESSWIRE
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
From MorphoSys AG
Via Business Wire
MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
From MorphoSys AG
Via Business Wire
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
Via ACCESSWIRE
MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
Via ACCESSWIRE
MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
Via ACCESSWIRE
MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
From MorphoSys AG
Via Business Wire
MorphoSys AG Reports First Quarter 2023 Financial Results
From MorphoSys AG
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.